Chemoresistance in Malignant Intracranial Tumors: Longer Survival with Negative MDR1 Expression

Basit Öğe Kaydı
dc.authoridKUL, Oguz/0000-0002-1282-650X
dc.contributor.authorEzgu, Mehmet Can
dc.contributor.authorKural, Cahit
dc.contributor.authorSimsek, Gulcin Guler
dc.contributor.authorKaygin, Pinar
dc.contributor.authorOguztuzun, Serpil
dc.contributor.authorKirik, Alparslan
dc.contributor.authorYasar, Soner
dc.date.accessioned2025-01-21T16:36:33Z
dc.date.available2025-01-21T16:36:33Z
dc.date.issued2021
dc.departmentKırıkkale Üniversitesi
dc.description.abstractAIM: To analyze the Glutathione S-transferase (GST)-P, GST-M, cytochrome p450 (CYP)1-A1, CYP1-B1, and multidrug resistance (MDR)-1 expressions in malignant intracranial tumor (ICT)s, and to elicit their role on patient survival. MATERIAL and METHODS: GST-P, GST-M, CYP1-A1, CYP1-B1, and MDR-1 expressions were analyzed using immunostaining in 149 samples from 141 patients with preoperative ICT diagnosis. The case characteristics were reviewed, and the enzyme expressions were equated based on the age, gender, and tumor type. Then, 77 of 141 patients with malignant ICT and complete medical records postoperative were also investigated in detail for the relationship between the diagnosis, enzyme expression, and overall survival. RESULTS: The average age was 49.44 years, with 83 (58.45%) male patients. Among the 77 malignant ICTs, 38 (49.3%) and 29 were glial tumors and metastases, respectively, with a 13.35-month overall survival. Patients with metastatic tumor have approximately threefold higher GSTP level than those with glial tumors. MDR-1 expression was approximately twofold higher in > 60-year-old patients. No statistically significant association was found between patients' smoking behaviors, alcohol consumption, and overall survival. Only MDR-1 expression was correlated with overall survival. Better overall survival was observed in patients with a negative MDR-1 expression than those with a positive one. CONCLUSION: MDR-1 is an important indicator of survival in malignant intracranial tumor patients. Longer survival is associated with negative MDR-1 expression.
dc.description.sponsorshipTurkish Neurosurgical Society
dc.description.sponsorshipThis study was partly supported by the Turkish Neurosurgical Society.
dc.identifier.doi10.5137/1019-5149.JTN.29819-20.3
dc.identifier.endpage459
dc.identifier.issn1019-5149
dc.identifier.issue3
dc.identifier.pmid33978213
dc.identifier.scopus2-s2.0-85107238433
dc.identifier.scopusqualityQ3
dc.identifier.startpage447
dc.identifier.urihttps://doi.org/10.5137/1019-5149.JTN.29819-20.3
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24332
dc.identifier.volume31
dc.identifier.wosWOS:000650214600021
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish Neurosurgical Soc
dc.relation.ispartofTurkish Neurosurgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241229
dc.subjectBrain; Tumor; Glutathione S-transferase; Cytochrome p450; Multidrug resistance
dc.titleChemoresistance in Malignant Intracranial Tumors: Longer Survival with Negative MDR1 Expression
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu